NEW YORK (GenomeWeb) – Nanostring Technologies today announced that its Prosigna Breast Cancer Assay has been acknowledged within the treatment guidelines of the German Association of Gynecological Oncology (AGO).

The company also said that a recent decision by the German Joint Federal Committee (G-BA) has qualified German breast cancer patients with statutory government insurance as eligible for coverage for gene expression testing, such as that provided by Prosigna, to inform therapy decisions beginning April 1.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.